Agenus (NASDAQ:AGEN – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.30, FiscalAI reports. The firm had revenue of $31.49 million for the quarter, compared to analyst estimates of $28.20 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.
Here are the key takeaways from Agenus’ conference call:
- Agenus said botensilimab (BOT) and balstilimab (BAL) are designed to activate immune responses in “cold” tumors. In early studies, the company reported activity across several cancer types, including a 21% response rate in metastatic colorectal cancer patients without active liver metastases.
- Early neoadjuvant studies in MSS colorectal cancer showed promising tumor responses: Agenus cited a 30% pathologic complete response rate in one study and said no patients treated with the combination had recurred at reported follow-up. These are early, relatively small studies and do not establish that the results will be replicated in a larger trial.
- The company plans an 850-patient Phase III trial, ROBIN, comparing BOT/BAL before surgery with standard care for high-risk stage II and stage III colon cancer. Agenus expects the regimen could improve event-free survival while reducing chemotherapy use, including exposure to oxaliplatin-related neuropathy.
- ROBIN’s key efficacy readouts remain years away: Agenus projected an interim event-free-survival analysis in the second half of 2029 and a full readout in the second half of 2030. The company’s potential additional $255 million in warrant proceeds depends on investor exercise, with the tranches tied to enrollment and interim response milestones.
Agenus Trading Up 11.0%
AGEN opened at $7.15 on Friday. The company has a fifty day simple moving average of $7.46 and a 200 day simple moving average of $5.01. Agenus has a twelve month low of $2.71 and a twelve month high of $10.31. The firm has a market cap of $322.89 million, a price-to-earnings ratio of 10.83 and a beta of 1.53.
Wall Street Analysts Forecast Growth
AGEN has been the subject of several recent research reports. Wall Street Zen downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Chardan Capital restated a “buy” rating on shares of Agenus in a research report on Thursday, October 22nd. Finally, Rodman & Renshaw began coverage on Agenus in a research note on Monday, September 28th. They issued a “buy” rating and a $19.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Agenus presently has an average rating of “Moderate Buy” and an average target price of $24.50.
Get Our Latest Stock Report on Agenus
Agenus Company Profile
Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.
Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.
The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.
Featured Articles
- Five stocks we like better than Agenus
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
